logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics on the potential of peanut vaccine

An Allergy Therapeutics (LON:AGY) breakthrough has the potential to protect against severe allergic reactions to peanuts, according to research carried by a leading academic journal.  

The single injection helped mice generate “sustained immunity and protection through vaccination”, helping prevent anaphylaxis.

CFO Nick Wykeman and CEO Manuel Llobet are pretty excited about the firm's early stage study and have a strong cash base to work from.
The data from the firm’s early-stage study was carried in The Journal of Allergy and Clinical Immunology, or JACI for short.

The first clinical trials of the vaccine are expected to get underway over the summer.
 

Quick facts: Allergy Therapeutics PLC

Price: 14.125 GBX

AIM:AGY
Market: AIM
Market Cap: £90.02 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics confident on the coming year as it reports 8% boost to...

Allergy Therapeutics PLC's (LON:AGY) Manuel Llobet and Nick Wykeman talk Proactive London's through the firm's preliminary results to June 2019. The vaccines specialist posted an 8% boost to revenues on a constant currencies basis to £73.7mln, giving ‘pre-R&D’ operating earnings of...

on 25/9/19

2 min read